Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 2/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29322620 | 0.74 | APLNR (0.40) | HTTSMN1; SMN2PIK3CDLMNAMAPT | |
| SCHEMBL27088502 | 0.74 | APLNR (0.40) | HTTSMN1; SMN2PIK3CDLMNAMAPT | |
| SCHEMBL29321909 | 0.74 | LMNA (0.41) | HTTSMN1; SMN2PIK3CDLMNAMAPT | |
| SCHEMBL17440767 | 0.72 | APLNR (0.43) | LMNAMAPTALDH1A1KMT2AQPCT | |
| SCHEMBL30897996 | 0.72 | LMNA (0.44) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL27089390 | 0.72 | LMNA (0.44) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL27089386 | 0.72 | LMNA (0.44) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL17441334 | 0.72 | ENPP2 (0.44) | HTTSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL25861665 | 0.67 | LMNA (0.46) | PKMLMNAMAPTALDH1A1CYP11B1 | |
| SCHEMBL22878730 | 0.67 | LMNA (0.51) | LMNAMAPTALDH1A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216762-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | CASR 3044/4885HTT 3772/4885SMN1; SMN2 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.